KRAS and cancer: In the BTC cohort of the KRYSTAL-1 trial targeting KRAS G12C–mutated cancers, patients treated with the KRAS G12C inhibitor adagrasib had an ORR of 41.7%, DCR of 91.7%, median progression-free survival of 8.6 months, and mOS of 15.1 months.21 However, the G12C variant was found in only approximately 6% of all KRAS-mutated BTCs.39 A number of pan-KRAS inhibitors are currently under development.37,40,41